Bilbao, Spain / Hong Kong, S.A.R. – November 21, 2014 Luqa Pharmaceuticals (“Luqa”), the China focused specialty pharmaceutical company, today announces the signing of a licensing agreement with Histocell for Reoxcare, a novel active dressing for hard-to-heal skin wounds to be commercialized in the People’s Republic of China, Hong Kong and Macau.
Reoxcare is an innovative wound dressing product with unique antioxidant properties that promotes a natural healing process in hard-to-heal skin wounds, such as chronic skin ulcers (pressure, vascular and diabetic) and traumatic or surgical wounds. Reoxcare’s unique design, based on the antioxidant properties of its components, is protected by an international patent until 2031. The first Luqa launches will take place in the mentioned territories by early 2015 following regulatory approvals.
Julio Font, CEO of Histocell said, “This collaboration confirms Histocell’s ability to move our product portfolio into fast-growing emerging markets through important partnerships. The agreement with Luqa ensures the launch of our product in the biggest Asian market, with a population of 1,300 million people that could benefit from the unique properties of Reoxcare.”
Robert Braithwaite, Luqa’s CEO said, “A key part of our vision is to continue to expand our product offering with a strategic focus on products for the skin. We are pleased to be partnering with Histocell for Reoxcare, an excellent product that will strengthen our portfolio and will contribute to our goal of becoming a leader in innovative and differentiated skin treatments in China.”
Histocell, S.L. is a biopharmaceutical company specialized in Medical Devices and Cell Therapy products for regenerative medicine. Currently, Histocell has a team of over 35 highly qualified professionals and production facilities are approved by the AEMPS (Spanish Agency of Medicinal products and Medical devices) in order to produce cell therapy drugs. Histocell’s technologies are based on the application of adult stem cells and bioactive materials as key technology, consolidating its position in the development of tissue engineering products. Specific therapeutic areas include: bone regeneration, cartilage regeneration, dermatology, neuro-protection and lung therapy.
Luqa Pharmaceuticals is a China-focused company. We acquire, develop and commercialize innovative healthcare products that bring added value to prescribers and other healthcare providers while enhancing quality of life for patients. Since its inception in 2010, Luqa has become a fast-growing revenue generating company with a broad product portfolio and pipeline. We aim to become a leader in specialty care segments in China.
For more information about Histocell, visit www.histocell.com
T. +34 94 656 7900
For more information about Luqa, visit www.luqapharma.com
T. +86 21 5237 6098